Overexpression of MicroRNA-200c Predicts Poor Outcome in Patients with PR-Negative Breast Cancer
Open Access
- 16 October 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e109508
Abstract
Micro-RNAs are small, noncoding RNAs that act as tumor suppressors or oncogenes. MiR-200c is a member of the miR-200 family; it is known to be dysregulated in invasive breast carcinoma. MiR-200c maintains the epithelial-mesenchymal transition and inhibits cell migration and invasion. Recent studies showed that miR-200c regulated steroid hormone receptors, estrogen receptors (ER), and progesterone receptors (PR). The present study aimed to detect miR-200c in 172 invasive breast carcinoma cases selected from a prospective cohort enrolled in Kuopio, Eastern Finland, between 1990 and 1995. MiR-200c expression was determined with relative q-PCR, and results were compared to clinicopathological variables and patient outcome. We found that PR status combined with miR-200c expression was a significant marker of outcome. High miR-200c expression was associated with reduced survival in PR-negative cases (n = 68); low miR-200c expression indicated reduced survival in PR-positive cases (n = 86) (Cox regression: P = 0.002, OR = 3.433; and P = 0.004, OR = 4.176, respectively). In PR-negative cases, high miR-200c expression was associated with shortened relapse-free survival (Cox regression: P = 0.001, OR = 3.613); increased local/distant recurrence (Logistic regression: P = 0.006, OR = 3.965); and more frequent distant metastasis (Logistic regression: P = 0.015, OR = 3.390). We also found that high grade and low stage tumors were positively correlated with high miR-200c expression (Logistic regression for high grade tumors: P = 0.002, OR = 2.791 and for high stage tumors: P = 0.035, OR = 0.285). Our results indicated that miR-200c may play a role in invasive breast carcinoma. Furthermore, miR-200c combined with PR status provided a refined predictor of outcome. In future, a larger study is required to confirm our results. This data may provide a basis for new research target–progesterone receptor–regulated microRNAs in breast cancer.Keywords
This publication has 54 references indexed in Scilit:
- Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic informationLaboratory Investigation, 2014
- MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast CancerDiscover Oncology, 2010
- miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and laborProceedings of the National Academy of Sciences, 2010
- mir-200c Regulates Induction of Apoptosis through CD95 by Targeting FAP-1Molecular Cell, 2010
- Causes and consequences of microRNA dysregulation in cancerNature Reviews Genetics, 2009
- The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional responseProceedings of the National Academy of Sciences, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cellsEMBO Reports, 2008
- MicroRNA expression profiles classify human cancersNature, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003